Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control.
作者信息
Lillegraven Siri, Paulshus Sundlisæter Nina, Aga Anna-Birgitte, Sexton Joseph, Solomon Daniel H, van der Heijde Désirée, Haavardsholm Espen A
机构信息
Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
JAMA. 2023 Mar 28;329(12):1024-1026. doi: 10.1001/jama.2023.0492.
Abstract
摘要
相似文献
1
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control.类风湿关节炎病情得到良好控制的患者停用传统合成改善病情抗风湿药物
JAMA. 2023 Mar 28;329(12):1024-1026. doi: 10.1001/jama.2023.0492.
2
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.半量与稳定剂量传统合成改善病情抗风湿药物对缓解期类风湿关节炎患者疾病复发的影响：ARCTIC REWIND随机临床试验
JAMA. 2021 May 4;325(17):1755-1764. doi: 10.1001/jama.2021.4542.
3
Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.类风湿关节炎患者停用英夫利昔单抗的两年结局：来自单中心的回顾性分析。
Intern Med. 2020;59(16):1963-1970. doi: 10.2169/internalmedicine.3934-19. Epub 2020 Aug 15.
4
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.未治疗的类风湿关节炎患者对包括甲氨蝶呤（MTX）在内的传统合成改善病情抗风湿药物（csDMARDs）反应不足的临床预测因素：一项单中心观察性研究。
Mod Rheumatol. 2020 Jan;30(1):50-57. doi: 10.1080/14397595.2018.1553265. Epub 2019 Jan 3.
5
Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.最适合与类风湿关节炎不同先进疗法联合使用的常规疾病修饰抗风湿药物：系统文献回顾与荟萃分析。
Arthritis Care Res (Hoboken). 2021 Jun;73(6):873-884. doi: 10.1002/acr.24195.
6
Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.评估类风湿关节炎患者管理中未满足的需求：来自 NOR-DMARD 登记处的分析。
Rheumatology (Oxford). 2019 Mar 1;58(3):481-491. doi: 10.1093/rheumatology/key338.
7
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.生物制剂改善病情抗风湿药的疗效：一项系统文献回顾，为 2013 年更新的 EULAR 类风湿关节炎管理建议提供信息。
Ann Rheum Dis. 2014 Mar;73(3):516-28. doi: 10.1136/annrheumdis-2013-204577. Epub 2014 Jan 7.
8
Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.类风湿关节炎的生物改善病情抗风湿药物的临床和治疗管理：RADAR 研究。
Rheumatol Int. 2019 Dec;39(12):2015-2024. doi: 10.1007/s00296-019-04378-6. Epub 2019 Aug 8.
9
Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.类风湿关节炎患者低疾病活动度下停止长期甲氨蝶呤治疗后 6 个月的 flares 风险。
Int J Rheum Dis. 2020 Aug;23(8):1076-1081. doi: 10.1111/1756-185X.13888. Epub 2020 Jul 6.
10
Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.类风湿关节炎中合并疾病修正抗风湿药物和甲氨蝶呤给药途径对生物治疗持久性的影响：OBRI 队列研究结果。
J Rheumatol. 2019 Aug;46(8):874-886. doi: 10.3899/jrheum.180486. Epub 2019 Apr 15.
引用本文的文献
1
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.肿瘤坏死因子抑制剂锥形与稳定治疗对缓解期类风湿关节炎患者疾病复发的影响：一项随机、开放标签、非劣效性试验。
Ann Rheum Dis. 2023 Nov;82(11):1394-1403. doi: 10.1136/ard-2023-224476. Epub 2023 Aug 22.
2
Incorrect Data in Table.表格中的数据有误。
JAMA. 2023 May 9;329(18):1612. doi: 10.1001/jama.2023.6906.
本文引用的文献
1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.EULAR 推荐的类风湿关节炎治疗方案：使用合成和生物疾病修正抗风湿药物：2022 更新版。
Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.
2
Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.免疫介导性炎症疾病患者的治疗策略
JAMA. 2021 May 4;325(17):1726-1728. doi: 10.1001/jama.2021.2740.
3
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.半量与稳定剂量传统合成改善病情抗风湿药物对缓解期类风湿关节炎患者疾病复发的影响：ARCTIC REWIND随机临床试验
JAMA. 2021 May 4;325(17):1755-1764. doi: 10.1001/jama.2021.4542.
4
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.无 DMARD 缓解作为类风湿关节炎的新型治疗目标：实现和可持续性的系统文献回顾。
RMD Open. 2020 May;6(1). doi: 10.1136/rmdopen-2020-001220.
5
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.稳定缓解的类风湿关节炎患者在减少或停止抗风湿治疗时的复发率：前瞻性随机对照 RETRO 研究的中期结果。
Ann Rheum Dis. 2016 Jan;75(1):45-51. doi: 10.1136/annrheumdis-2014-206439. Epub 2015 Feb 6.
Zotero 插件